You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康哲藥業(00867.HK)簽訂治療自身免疫性疾病產品許可協議
阿思達克 09-22 04:18
康哲藥業(00867.HK)公布,與medac就於歐洲和美國上市的標準治療產品簽訂經銷、供應及許可協議。據此,公司獲得在中國、香港、澳門及台灣使用由medac擁有或控制的所有相關知識產權和知識產權權利開發、註冊及商業化產品的獨家許可權利。

產品包括類風濕關節炎和其他自身免疫性疾病的一線替代療法—甲氨蝶呤預充式注射器/注射筆,以及非肌層浸潤性膀胱癌的金標準免疫療法—膀胱灌注用卡介苗,針對的疾病均於區域存在未被滿足的臨床需求。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account